| Literature DB >> 28731719 |
Agnès Joncour1, Nicolas Desroy1, Christopher Housseman1, Xavier Bock1, Natacha Bienvenu1, Laëtitia Cherel1, Virginie Labeguere1, Christophe Peixoto1, Denis Annoot1, Luce Lepissier1, Jörg Heiermann2, Willem Jan Hengeveld2, Gregor Pilzak2, Alain Monjardet1, Emanuelle Wakselman1, Veronique Roncoroni1, Sandrine Le Tallec1, René Galien1, Christelle David1, Nele Vandervoort3, Thierry Christophe3, Katja Conrath3, Mia Jans3, Alexandre Wohlkonig4, Sameh Soror4, Jan Steyaert4, Robert Touitou1, Damien Fleury1, Lionel Vercheval1, Patrick Mollat1, Nicolas Triballeau1, Ellen van der Aar3, Reginald Brys3, Bertrand Heckmann1.
Abstract
Autotaxin (ATX) is a secreted enzyme playing a major role in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl choline (LPC). The ATX-LPA signaling axis arouses a high interest in the drug discovery industry as it has been implicated in several diseases including cancer, fibrotic diseases, and inflammation, among others. An imidazo[1,2-a]pyridine series of ATX inhibitors was identified out of a high-throughput screening (HTS). A cocrystal structure with one of these compounds and ATX revealed a novel binding mode with occupancy of the hydrophobic pocket and channel of ATX but no interaction with zinc ions of the catalytic site. Exploration of the structure-activity relationship led to compounds displaying high activity in biochemical and plasma assays, exemplified by compound 40. Compound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28731719 DOI: 10.1021/acs.jmedchem.7b00647
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446